There’s a lot of concern and confusion right now about the new #sarscov2 variant identified in UK. I’ve spent today and yesterday talking to a dozen people working on this. My story is here: sciencemag.org/news/2020/12/m…
Thread to come (may be long and slow)
There are a ton of things to explain, dozens of questions to discuss and I won’t be able to cover more than a tiny part here now. So three general things up front: 1. Expect more threads and stories on this from me
It’s becoming clearer that one main hypothesis that scientists are looking at with B.1.1.7 is whether its advantage could be that it is better at infecting children. There are a TON of caveats, but this is one possibility that is being explored.
The idea is very simple: #SARSCoV2 appears to be a bit worse at infecting children than adults. If the mutations in B.1.1.7 allow this variant to bind more tightly to the ACE2 receptor on human cells that could essentially make it as good at infecting children as adults.
Like I said a TON of caveats. Maybe most importantly: the UK had a lockdown while schools were kept open, so you would expect the epidemic to shift more to children anyway and that of course can make it look like there is something going on with this variant in children.
“We urge governments throughout Europe to agree on clearly formulated common goals, coordinate their efforts, develop regionally adapted strategies to reach the goals, and thereby work resolutely towards low case numbers”, @CiesekSandra, @ViolaPriesemann and others in @TheLancet
The lack of a European strategy is something scientists and public health experts have pointed out again and again and it’s good to see it clearly formulated by a group of prominent researchers thelancet.com/journals/lance…
The authors also give a good, succinct summary of arguments for going for low #covid19 case numbers: 1. saving lives 2. saving the economy 3. control is more effective 4. makes TTI feasible 5. natural acquired herd immunity is not an option 6. no need for rapid policy changes
Meine Kollegen vom @pandemiapodcast und ich haben viele Fragen bekommen in den vergangenen Wochen zu den neuen Impstoffen, zu ihrer schnellen Entwicklung, ihrer Sicherheit, zu Impfbereitschaft und Impfpflicht. Wir wollten das natürlich aufnehmen.
@pandemiapodcast Die neue Folge ist darum ein etwas wilder Ritt querfeldein und wir binden zusammen, worüber wir in den ersten Folgen der zweiten Staffel gesprochen haben: Impfstoffe, Pocken, Masern und eben #SARSCoV2. Die Folge gibt es hier: viertausendhertz.de/pan16/
Als Nächstes dann Gelbfieber!
Global vaccine news: COVAX says deals are in place to access nearly 2 billion doses of #covid19 vaccine. "For the vast majority of these deals, COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available”
The new deals include:
- an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate
- a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate (investigated as single dose vaccine)
That’s on top of:
- agreement with Serum Institute of India for 200 million doses (plus option for 900 million more doses) of either AZ or Novavax vaccine
- statement of intent for 200 million doses of Sanofi/GSK vaccine candidate
Science asked me to -briefly- reflect on what happened in 2020. So, a thread on this year in science, the breakthroughs and breakdowns and where my head is at at the end of this difficult year.
First, read @sciencecohen's beautiful, personal story on the vaccines:
“I can stop worrying about my mom dying alone in an intensive care unit, away from all who love her. And she can stop asking whether I’ll let her play mahjong with the girls”
@sciencecohen The rapid development of efficacious #covid19 vaccines was clearly the science breakthrough of the year. But what about all the rest that went on in #covid19 science? My story is labeled “breakdown”, but the picture is complicated.
Expected, but still good #covid19 vaccine news for Europe: @EMA_News has now moved up the likely date for Moderna vaccine as well. Meeting now scheduled for January 6 instead of January 12. Means vaccination with second vaccine likely to start a week earlier than thought in EU.
@EMA_News "Today, ahead of schedule, the company has submitted the last outstanding data package needed for the assessment of the application. This contains information that is specific to the manufacturing of the vaccine for the EU market“, says EMA press release.
@EMA_News "The number of infections is increasing across Europe and we are aware of the huge responsibility we have to get a vaccine to the market as quickly as is feasible, whilst maintaining the robustness of our scientific review”, EMA head Emer Cooke says in the press release.